Biontech Ag

Thomas Wuest

Klaus Pfizenmaier

Dieter Moosmayer

Harald Wajant

Urs Schaffhauser

Lukas Zeder

Christoph Schuler

Rene Strebel

Beat Brugger

Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.

Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZe (antibody-mediated apoptosis inducing cytokines)

Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumor tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimized for the respective indication/tumor entity.

Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines)

Growing community of inventors

Dietikon, Switzerland

Thomas Wuest